NPPA caps prices of 43 drug formulation packs

National Pharmaceutical Pricing Authority (NPPA) has capped the prices of 43 formulation packs including drugs such as antibiotic Ciprofloxacin, BCG vacine and anti-diabetic Metformin.
"The prices have been fixed / revised in respect of 43 formulation packs, both ceiling and retail price packs, under DPCO, 2013," NPPA said.
The drug price regulator said the manufacturers of above mentioned formulations having maximum retail price higher than the ceiling price specified shall revise the MRP to an amount not exceeding the ceiling price plus local taxes, wherever applicable in accordance with paragraph 13 (1) and 24 of the DPCO,2013.
Major drug companies including Cipla, Ranbaxy, Lupin and Cadila are likely to be impacted as a result of the price control.

Commenting on the development, Angel Broking VP Research - Pharma Sarabjit Kour Nangra said: "This would have near term impact on the companies."
In July this year NPPA had reduced the prices of some of the key medicines and had fixed the price of 108 non-scheduled formulation packs of 50 anti-diabetes and cardiac medicines.
The drugs that were to become cheaper included key medicines such as atorvastatin, gliclazide, glimepiride, hepa rin and metolazone, among others.